| |
|
|
|
|
|
|
|
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
|
|
Vancouver, BC, May 5, 2022--AbCellera (Nasdaq: ABCL) and Empirico Inc. announced that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico's Precision Insights Platform to discover genetically validated drug targets and AbCellera's technology to identify lead candidate antibodies against those targets.
|
|
|
|
|
|
|
|
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
|
|
Vancouver, BC, April 19, 2022--AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
|
|
|
|
|
|
|
|
|
|
|
|
Eli Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab (Worth $720 Million), to the U.S. Government
|
|
Vancouver, BC, February 11, 2022--AbCellera (Nasdaq: ABCL) announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera's collaboration with Lilly.
|
|
|
|
|
|
|
|
AbCellera Announces Changes to Its Board of Directors
|
|
Vancouver, BC, December 16, 2021--AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately.
|
|
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
